Article info

Download PDFPDF

Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
Free

Authors

  1. Correspondence to Dr Graham Morrison, Gastroenterology, Belfast Health and Social Care Trust, Belfast BT13 1FD, UK; graham.morrison{at}belfasttrust.hscni.net
View Full Text

Citation

McGoran J, Wilson A, McErlain S, et al
Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Publication history

  • Received December 20, 2020
  • Revised April 8, 2021
  • Accepted April 18, 2021
  • First published May 27, 2021.
Online issue publication 
December 07, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.